JP2018502828A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502828A5
JP2018502828A5 JP2017527368A JP2017527368A JP2018502828A5 JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5 JP 2017527368 A JP2017527368 A JP 2017527368A JP 2017527368 A JP2017527368 A JP 2017527368A JP 2018502828 A5 JP2018502828 A5 JP 2018502828A5
Authority
JP
Japan
Prior art keywords
mutations
lung cancer
aforementioned
immune checkpoint
synonymous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017527368A
Other languages
English (en)
Japanese (ja)
Other versions
JP7173733B2 (ja
JP2018502828A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/062208 external-priority patent/WO2016081947A2/en
Publication of JP2018502828A publication Critical patent/JP2018502828A/ja
Priority to JP2022129458A priority Critical patent/JP7550193B2/ja
Publication of JP2018502828A5 publication Critical patent/JP2018502828A5/ja
Application granted granted Critical
Publication of JP7173733B2 publication Critical patent/JP7173733B2/ja
Priority to JP2024107117A priority patent/JP2024125234A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017527368A 2014-11-21 2015-11-23 Pd-1遮断による免疫療法の癌奏効の決定因子 Active JP7173733B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022129458A JP7550193B2 (ja) 2014-11-21 2022-08-16 Pd-1遮断による免疫療法の癌奏効の決定因子
JP2024107117A JP2024125234A (ja) 2014-11-21 2024-07-03 Pd-1遮断による免疫療法の癌奏効の決定因子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US62/083,088 2014-11-21
US201562132381P 2015-03-12 2015-03-12
US62/132,381 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020135853A Division JP2020196732A (ja) 2014-11-21 2020-08-11 Pd−1遮断による免疫療法の癌奏効の決定因子
JP2022129458A Division JP7550193B2 (ja) 2014-11-21 2022-08-16 Pd-1遮断による免疫療法の癌奏効の決定因子

Publications (3)

Publication Number Publication Date
JP2018502828A JP2018502828A (ja) 2018-02-01
JP2018502828A5 true JP2018502828A5 (cg-RX-API-DMAC7.html) 2022-09-01
JP7173733B2 JP7173733B2 (ja) 2022-11-16

Family

ID=56014697

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017527368A Active JP7173733B2 (ja) 2014-11-21 2015-11-23 Pd-1遮断による免疫療法の癌奏効の決定因子
JP2020135853A Withdrawn JP2020196732A (ja) 2014-11-21 2020-08-11 Pd−1遮断による免疫療法の癌奏効の決定因子
JP2022129458A Active JP7550193B2 (ja) 2014-11-21 2022-08-16 Pd-1遮断による免疫療法の癌奏効の決定因子
JP2024107117A Pending JP2024125234A (ja) 2014-11-21 2024-07-03 Pd-1遮断による免疫療法の癌奏効の決定因子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020135853A Withdrawn JP2020196732A (ja) 2014-11-21 2020-08-11 Pd−1遮断による免疫療法の癌奏効の決定因子
JP2022129458A Active JP7550193B2 (ja) 2014-11-21 2022-08-16 Pd-1遮断による免疫療法の癌奏効の決定因子
JP2024107117A Pending JP2024125234A (ja) 2014-11-21 2024-07-03 Pd-1遮断による免疫療法の癌奏効の決定因子

Country Status (8)

Country Link
US (3) US20180291074A1 (cg-RX-API-DMAC7.html)
EP (2) EP4393546A3 (cg-RX-API-DMAC7.html)
JP (4) JP7173733B2 (cg-RX-API-DMAC7.html)
CN (2) CN114672559A (cg-RX-API-DMAC7.html)
AU (3) AU2015349644B2 (cg-RX-API-DMAC7.html)
HK (1) HK1244440A1 (cg-RX-API-DMAC7.html)
MA (1) MA40737A (cg-RX-API-DMAC7.html)
WO (1) WO2016081947A2 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
HUE054012T2 (hu) 2014-10-29 2021-08-30 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
US11725247B2 (en) 2016-02-29 2023-08-15 Foundation Medicine, Inc. Methods of treating cancer
WO2017151502A1 (en) 2016-02-29 2017-09-08 Genentech, Inc. Therapeutic and diagnostic methods for cancer
JP6918816B2 (ja) * 2016-03-01 2021-08-18 ノース カロライナ ステート ユニバーシティ マイクロニードルパッチ支援送達による強化されたがん免疫療法
JP7147168B2 (ja) * 2016-03-02 2022-10-05 東レ株式会社 免疫誘導剤
KR102543118B1 (ko) 2016-05-27 2023-06-14 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
US11359017B2 (en) 2016-07-01 2022-06-14 Tohoku University Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
AU2017315468B2 (en) 2016-08-25 2020-02-13 Nantomics, Llc Immunotherapy markers and uses therefor
KR102804118B1 (ko) * 2016-10-06 2025-05-09 제넨테크, 인크. 암에 대한 치료 및 진단 방법
JP7295015B2 (ja) 2016-10-07 2023-06-20 オムニセック インコーポレイテッド 個別化治療を決定するための方法
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
ES2885178T3 (es) * 2017-02-06 2021-12-13 Novartis Ag Método para la predicción de respuesta a la inmunoterapia
US20190360051A1 (en) * 2017-02-17 2019-11-28 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
EP3601536A4 (en) * 2017-03-20 2021-01-13 Genocea Biosciences, Inc. TREATMENT PROCEDURES
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
AU2018304458B2 (en) * 2017-07-21 2021-12-09 Foundation Medicine, Inc. Therapeutic and diagnostic methods for cancer
US11899017B2 (en) * 2017-07-28 2024-02-13 Bristol-Myers Squibb Company Predictive peripheral blood biomarker for checkpoint inhibitors
JP2020535119A (ja) * 2017-09-13 2020-12-03 ファイヴ プライム セラピューティクス インク 膵臓がんの抗csf1rおよび抗pd−1抗体組合せ併用療法
US20200268831A1 (en) * 2017-09-15 2020-08-27 The Texas A&M University System Methods for enhancing immunotherapy in the treatment of cancer
AU2018338441B2 (en) 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
CA3076918A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
WO2019075251A2 (en) * 2017-10-12 2019-04-18 Nantomics, Llc CANCER SCORE FOR EVALUATION AND PREDICTION OF RESPONSE FROM BIOLOGICAL FLUIDS
EP3694884A1 (en) * 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
WO2019095017A1 (en) * 2017-11-17 2019-05-23 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
EP3622522A1 (en) 2017-12-01 2020-03-18 Illumina, Inc. Methods and systems for determining somatic mutation clonality
EP3788173B1 (en) 2018-05-03 2023-11-29 F. Hoffmann-La Roche AG Surrogate marker and method for tumor mutation burden measurement
BR112020022145A2 (pt) * 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
CN120193081A (zh) 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
US20210292851A1 (en) 2018-07-27 2021-09-23 Roche Sequencing Solutions, Inc. Method of monitoring effectiveness of immunotherapy of cancer patients
WO2020045479A1 (ja) 2018-08-29 2020-03-05 公益財団法人東京都医学総合研究所 HGF-regulated tyrosine kinase substrate(HGS)を標的とした抗腫瘍剤
JP7539367B2 (ja) 2018-08-31 2024-08-23 ガーダント ヘルス, インコーポレイテッド 無細胞dnaにおけるマイクロサテライト不安定性の検出
CA3120200A1 (en) 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
WO2020121226A1 (en) * 2018-12-12 2020-06-18 Medimmune, Llc Blood-based tumor mutation burden predicts overall survival in non-small cell lung cancer
EP3982954A4 (en) 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
EP4051314A4 (en) * 2019-11-01 2023-12-06 Memorial Sloan Kettering Cancer Center Hla class i sequence divergence and cancer therapy
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
EP4143345A1 (en) * 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
US20230242992A1 (en) * 2020-06-01 2023-08-03 Gmdx Co Pty Ltd Methods of predicting cancer progression
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
CA3200667A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
US20240238340A1 (en) * 2021-05-03 2024-07-18 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN122003713A (zh) 2023-04-12 2026-05-08 西奈山伊坎医学院 用于选择个性化新抗原疫苗的计算方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
JP6002659B2 (ja) * 2010-04-13 2016-10-05 セルデックス・セラピューティクス・インコーポレイテッド ヒトcd27に結合する抗体およびその使用
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
WO2013130748A1 (en) * 2012-02-29 2013-09-06 The Regents Of The University Of Michigan Prostate cancer markers and uses thereof
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
SG11201605432RA (en) * 2014-01-02 2016-07-28 Sloan Kettering Inst Cancer Determinants of cancer response to immunotherapy
KR20170080697A (ko) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Similar Documents

Publication Publication Date Title
Succony et al. Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
JP7497084B2 (ja) がん治療の有効性を予測するためのシステムおよび方法
Perdomo et al. Circulating tumor DNA detection in head and neck cancer: evaluation of two different detection approaches
Liu et al. Heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma
Shay et al. Bacteriome and mycobiome and bacteriome-mycobiome interactions in head and neck squamous cell carcinoma
CN114540499A (zh) 基于pcd相关基因组合构建的模型在制备预测结肠腺癌预后产品中的应用
US20200109455A1 (en) Systems and methods for predicting clinical responses to immunotherapies
JP2023521280A (ja) 免疫防御応答遺伝子に基づく、前立腺がん対象者のための放射線治療応答の予測
Li et al. Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer
Bogusz et al. Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Abazari et al. Estimation of survival rates in patients with lung cancer in west Azerbaijan, the northwest of Iran
Aoki et al. Greater extent of blood‐tumor TCR repertoire overlap is associated with favorable clinical responses to PD‐1 blockade
Li et al. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy
Li et al. Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors
CN105574365A (zh) 高通量测序突变检测结果的统计学验证方法
Campo-Le-Brun et al. Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: an AGEO study
Devarakonda et al. Next-generation sequencing of lung cancers: Lessons learned and future directions
JP2014515477A5 (cg-RX-API-DMAC7.html)
Thursby et al. Epigenetic Instability–Based Metrics in Cell-Free DNA for Early Cancer Detection
Guo et al. Phase II trial of neoadjuvant camrelizumab and apatinib in resectable NSCLC: 3-year survival outcomes and dynamic circulating tumor DNA analyses
Inokuchi et al. Cadherin 5 is a significant risk factor for hematogenous recurrence and a prognostic factor in locally advanced gastric cancer
Sklodowski et al. 59 Integrating deep proteomics profiling with survival analysis to identify novel biomarkers of response to PD-1 blockade in NSCLC patients
Luna et al. 55P CTC count & gene expression profiling among Filipino NSCLC
Potempa-Jeziorowska Salivary biomarkers for monitoring the course of cancer development–real perspectives
Chen et al. 169p anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase ii clinical study